Teva value up $2.6bn following OxyContin patent win, JPM appearance
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries saw its share price rise by 6.7% on 14 January after the company won a US patent dispute with Purdue Pharma over an abuse-proof version of the pain product OxyContin (oxycodone). The uptick added $2.6bn to the company's market capitalization on NYSE, where its ADRs are traded: it closed at $41.9bn.